Articles tagged with Drug Resistance
Researchers have identified a novel tyrosine kinase inhibitor that targets both resistant tumors and FLT3-independent AML. The compound, MRX-2843, exhibits antitumor effects in culture and preclinical models, improving survival rates even in cases of tumors resistant to existing treatments.
A new study finds that CDK4/6 inhibitor abemaciclib can restore sensitivity to HER2-targeted treatments in breast cancer cells, overcoming drug resistance. The agent's effectiveness was confirmed in mouse models and paves the way for a clinical trial.
Researchers developed insights to guide powerful new anti-influenza drug development by analyzing artificially created drug-resistant flu strains' molecular details. The compounds target the endonuclease active site, a region where viruses can mutate to evade existing drugs.
A Cancer Research UK-funded study suggests an HIV drug could block the molecular switch that boosts cells' ability to survive treatment, making treatments more potent and delaying drug resistance. The research, carried out in mice, implies that nelfinavir could be used to combat melanoma skin cancers.
A study published in the New England Journal of Medicine found that dihydroartemisinin-piperaquine (DP) was effective in preventing malaria in pregnancy, with no reported cases among women taking monthly doses. The therapy showed better results than sulfadoxine-pyrimethamine (SP), a widely used but ineffective option due to widespread ...
Researchers at Ohio State University have developed a DNA 'Trojan horse' that can deliver cancer drugs into resistant cells, effectively killing them. The capsule made of folded up DNA hides the invading force, allowing it to bypass cell defenses and accumulate in cancer cells.
Scientists have developed a new drug targeting the malaria parasite's proteasome, which could combat the growing resistance to first-defence treatments. The innovative approach has shown promising results in killing resistant parasites and may complement existing artemisinin drugs.
Analyzing tumor DNA fragments in the bloodstream can give a more complete picture of a patient's cancer. Researchers found that standard practice of performing molecular testing on a single metastatic lesion may be inadequate, and circulating tumor DNA testing may better capture the molecular diversity in a patient's tumor.
Scientists at Helmholtz Zentrum München discover that Cistus incanus extracts prevent human immunodeficiency viruses from infecting cells and block Ebola- and Marburg viral envelope proteins. The study demonstrates broad antiviral activity of Ci extracts against various major human viral pathogens.
A new study suggests that the standard practice of treating infections with high doses of anti-microbe medications may not be the best way to prevent drug resistance in all cases. The researchers found that using the highest dose that is safe may be more effective than using the lowest dose that is effective in preventing drug resistance.
A large study found tenofovir-resistant strains in 60% of HIV patients in sub-Saharan Africa, highlighting a significant concern for global HIV control strategies. The study suggests that up to 15% of HIV patients will develop resistance in the first year of treatment alone.
A recent study found that dihydroartemisinin-piperaquine treatment has failed in certain provinces of Cambodia due to parasite resistance. The WHO has reinstated artesunate plus mefloquine as the first-line treatment in these areas. New surveillance and clinical trials are needed to track the spread of piperaquine resistance.
Researchers have discovered a triple therapy approach that could make treatment-resistant lung cancers susceptible to therapy. The combination of two experimental drugs and radiation therapy was found to be effective in mice with KRAS-related gene mutations.
Researchers discovered a novel mechanism of resistance and re-sensitization to first-generation ALK inhibitors in a patient with metastatic non-small-cell lung cancer. The study highlights the importance of repeat biopsies and molecular profiling to uncover novel resistance mechanisms.
A team of NUS researchers discovered over 120 protein targets of artemisinin in Plasmodium falciparum, the most pathogenic malaria parasite. The study found that haem is the main activator of artemisinin, which targets essential biological processes in the parasite.
A Georgetown University Medical Center researcher is leading a multi-institutional effort to investigate the causes of rising drug-resistant malaria parasites. The study aims to understand molecular mechanisms responsible for this increasing resistance and develop new therapies.
Researchers found that combining palbociclib with paclitaxel shrank tumors in nearly half of patients with estrogen-receptor positive breast cancer. The combination appears to be safe and may offer benefits over paclitaxel alone, suggesting a larger clinical trial is warranted.
Researchers at Eindhoven University of Technology have identified a novel site on the RORγt nuclear receptor that can be targeted by drugs without inducing resistance. This discovery could lead to new treatments for autoimmune diseases like rheumatism and Crohn's disease.
Researchers identified 13 hotspot CNVs associated with JME and found that drug resistance enriches a clinical cohort for common CNVs. This study provides new insights into the genetic basis of JME and highlights the need for further molecular biology studies.
Studies reveal that different types of autoimmune responses elicit distinct responses in patients with drug-resistant epilepsy. Antibodies targeting intracellular proteins lead to a worse prognosis and poorer response to immunotherapy compared to those against cell surface proteins.
A team of researchers developed a model to predict the effects of parasite refugia on disease prevalence and drug resistance. The model suggests that introducing drug-susceptible parasites into a population can reduce overall drug resistance.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a promising new melanoma drug, SBI-756. The compound targets the translation initiation complex and has been shown to inhibit melanoma cell growth. SBI-756 may offer a significant advantage in overcoming tumor resistance.
A mass drug administration (MDA) program implemented in Southern Greece eliminated malaria cases for two years, preventing a resurgence of the disease. The MDA covered 87% of an immigrant population and was effective in minimizing the risk of drug resistance.
A Vanderbilt study found that sildenafil improves insulin sensitivity in people at risk for diabetes, potentially reducing the risk of developing type 2 diabetes. The researchers discovered that sildenafil inhibits an enzyme called phosphodiesterase 5, resulting in relaxation of smooth muscle and increased blood flow.
Researchers have discovered a new mechanism of drug resistance in metastatic prostate cancer cells, which can be predicted using protein levels. The study found that high levels of 4EBP1 protein lead to decreased protein synthesis and resistance to PI3K pathway inhibitors.
A 2-year-old girl was diagnosed and treated for XDR TB, the first detailed account of a young child in the US. The successful treatment highlights the need for better understanding and creative approaches to pediatric tuberculosis.
A computer simulation study suggests that treating malaria with a combination of more effective and less effective drugs can slow the spread of drug-resistant parasites. The non-artemisinin therapy, even when only 85% effective, works best in this approach.
Researchers have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug. The test predicts which patients will not respond to treatment and can inform personalized treatment options.
Researchers identified VRAC channels as responsible for half of anti-cancer drug uptake, with down-regulated subunits linked to therapy resistance and programmed cell death disturbances. The study's findings hold high clinical relevance and suggest potential new targets for overcoming cancer therapy resistance.
Researchers explored the use of ivermectin in mass drug administration campaigns to reduce malaria infections in Africa and slow down drug resistance in Asia. Preliminary results showed a 16% reduction in childhood malaria episodes in Burkina Faso, where most population members received regular ivermectin doses.
A study found that sirolimus successfully resolved autoimmune conditions in children with ALPS without adverse side effects. The treatment improved blood cell counts and quality of life for patients, making it a potential early therapy option.
A study published in the Journal of Virological Methods found that Bio-Rad's Droplet Digital PCR (ddPCR) technology significantly increases the sensitivity and precision of mutation abundance quantification when compared to RT-qPCR. This makes it an ideal tool for detecting viral RNA mutations in clinical samples.
Researchers found developing resistance to miltefosine in patients with post-kala-azar dermal leishmaniasis, leading to higher relapse rates. The study suggests a pressing need for new therapies to combat drug-resistant strains of the disease.
Garden-variety staph infections are just as deadly for newborns as drug-resistant strains, according to a study by Johns Hopkins Medicine. Nonresistant bacterial infections affect more than twice as many babies and have the same high mortality rate as their drug-resistant cousins.
A new method allows patients to get effective treatment quickly with improved sensitivity and speed. The system operates directly on the virus' RNA rather than requiring extra steps, enabling faster detection of drug-resistant strains.
A novel hyperthermia method has been developed for preventing and treating Schistosomiasis japonica by targeting migrating skin schistosomula. The treatment shows promising results in reducing the survival rate of cercariae and worm reduction rates, offering a potential alternative to PZQ.
A new study found that drug-resistant E. coli infections are rising in community health settings, with cases doubling from 5.28 to 10.5 incidents per 100,000 patients between 2009 and 2014.
Over 15 years, malaria cases in Africa have decreased by 663 million, mainly due to bednet and ACT interventions. However, growing insecticide and drug resistance threaten these efforts, requiring a proactive approach to develop new antimalarial drugs and insecticides.
A new study from Duke University Medical Center found that using a combination of chemicals and UV light to clean patient rooms reduces the transmission of four major superbugs by 30 percent among overnight patients. This method was more effective than standard cleaning strategies, which often fail to eliminate germs on surfaces.
Researchers evaluated two alternative strategies to prevent malaria in pregnancy, finding that dihydroartemisinin-piperaquine reduced clinical malaria by 84% and risk of anaemia by 22%. The new drug was also associated with lower risks of stillbirths and infant mortality.
Researchers have identified a molecular pathway that explains how tamoxifen-resistant breast cancer cells develop. The 'feedback loop' involves the HOXB7 protein, which helps activate genes that promote cancer growth. Targeting MYC protein, which is involved in this pathway, may lead to new treatments for tamoxifen-resistant cancers.
Western University researchers have developed an artificial intelligence-powered tool that can predict a patient's response to paclitaxel and gemcitabine chemotherapy medications. The tool uses genetic analysis of tumours to identify the genetic signatures most important for determining resistance and remission for each medication. Wit...
Researchers at the University of Manchester have discovered a potential new approach to overcome hormone therapy resistance in ER+ breast cancer by targeting breast cancer stem cells driven by NOTCH4. This approach shows promise in improving treatment outcomes for patients with hormone therapy-resistant breast cancer.
Researchers have developed a combination of three antibiotics that can effectively treat methicillin-resistant Staphylococcus aureus (MRSA) infections in test tubes and laboratory mice. The synergistic action of the drugs prevents MRSA from developing resistance, offering potential treatment against this deadly pathogen.
Cancer patients who receive chemotherapy treatment for a sustained period have heightened levels of reactive oxygen species (ROS), which correlates with drug resistance. The study proposes a measure of relative ROS levels under normal conditions to help determine if patients are becoming resistant to cancer drugs.
Researchers discover that altering protein recycling complexes in human cells enables cancer cells to resist treatment with proteasome inhibitors, a class of drugs used to kill cancer cells. The discovery highlights the potential for targeting this resistant state to develop new cancer treatments.
ESC Congress 2015 saw a record-breaking attendance of 32,773 registrations, featuring 28 clinical Hot Line presentations, 18 Clinical Trial Updates, and 20 Registry studies. Key findings included the use of spironolactone for resistant hypertension and its positive implications for clinical practice.
Researchers have discovered a chestnut leaf extract that blocks Staphlococcus aureus virulence and pathogenesis without detectable resistance. The extract, rich in ursene and oleanene derivatives, shuts down the ability of the bacteria to create toxins by taking away its weapons.
Researchers are monitoring drug resistance to HIV prevention drugs in sub-Saharan Africa through a $5 million initiative. The project aims to prevent new infections and develop cost-effective diagnostic plans.
Researchers have established the safety and dosing of a new drug for treating blood cancers, targeting dormant cancer stem cells. The drug coaxes these cells to differentiate and exit the bone marrow, where they can be destroyed by chemotherapy agents.
Scientists have identified a potent agent, DSM265, that thwarts drug resistance in malaria parasites. This breakthrough treatment has the potential to be used for both single-dose and once-weekly doses, offering new hope against the disease.
Researchers at Johns Hopkins have found that combining fostamatinib with paclitaxel can reduce tumor size in ovarian cancer cells by up to 87 percent. The combination therapy may provide a new treatment option for patients with recurrent advanced ovarian cancer who have developed resistance to standard treatments.
A new detection method has been developed to rapidly and accurately detect drug-resistant HCV mutants, including the Y93H mutation. The system achieved a high success rate of 98.9% in detecting this mutation in Japanese HCV genotype 1b patients.
A commentary in CMAJ argues that tamper-resistant opioids will not address the root causes of opioid addiction and overdose. Experts call for an evidence-based, multifaceted strategy to curb opioid-related harms.
Researchers developed targeted nanoparticles that deliver existing drugs directly into parasite cells, reducing the curative dose by 100-fold and circumventing drug resistance. This high-tech approach has the potential to reverse resistance to many first-line treatments for infectious diseases.
A systematic review and meta-analysis of 90 studies found residents of modern homes were 47% less likely to be infected with malaria than those living in traditional houses. Modern housing features, such as closed eaves, ceilings, screened doors and windows, can block mosquitoes from entering homes and prevent transmission of the disease.
Researchers at Northeastern University have identified dormant persister cells in Borrelia burgdorferi that evade antibiotics. Two potential methods to eradicate the infection were also found, including pulse-dosing an antibiotic to eliminate persisters.
Sanford-Burnham researchers have identified a new molecular pathway, JAK1, that drives resistance to BRAF inhibitor treatment in melanoma tumors. Targeting JAK1 may improve the effectiveness of current therapy for patients with drug-resistant melanoma.
A recent study found that the thunder god vine extract reduces food intake by up to 80% and causes a 45% decrease in body weight in obese mice. The compound Celastrol enhances leptin action, a hormone signaling fullness to the brain, improving ER function and sensitivity.
A new study shows that physical resistance training significantly improves sexual function, desire, arousal, and lubrication in women with polycystic ovary syndrome. Additionally, it decreases anxiety and depression, suggesting a useful intervention for these individuals.